Table 1.
Baseline characteristics of subcohort participants according to quartiles of fibroblast growth factor 23
| Variable | Fibroblast Growth Factor 23, pg/ml | ||||
|---|---|---|---|---|---|
| All Participants (40.0; n=590) | Quartile 1 (<31.9; n=150) | Quartile 2 (31.9–39.9; n=147) | Quartile 3 (40.0–50.2; n=146) | Quartile 4 (≥50.3; n=147) | |
| Age, yr | 61.8±6.3 | 61.8±5.8 | 61.0±6.6 | 61.8±6.3 | 62.6±6.5 |
| Women (%) | 46.0 | 42.7 | 38.8 | 47.3 | 53.7 |
| Black (%) | 18.8 | 21.3 | 19.7 | 18.5 | 15.6 |
| Hispanic (%) | 4.4 | 5.3 | 6.1 | 3.4 | 2.7 |
| Hypertension (%) | 88.6 | 86.7 | 85.0 | 92.0 | 91.2 |
| History of stroke (%) | 5.8 | 8.0 | 5.4 | 4.8 | 4.8 |
| History of myocardial infarction (%) | 14.8 | 17.3 | 15.0 | 15.8 | 10.8 |
| History of heart failure (%) | 6.3 | 8.1 | 7.6 | 6.2 | 3.4 |
| Current smoking (%) | 11.7 | 10.7 | 17.0 | 11.6 | 7.5 |
| Body mass index, kg/m2 | 32.3±5.7 | 31.9±5.3 | 31.1±5.8 | 32.7±5.4 | 33.6±5.9 |
| Systolic BP, mmHg | 134.4±16.2 | 134.1±16.5 | 133.6±15.8 | 135.0±15.8 | 135.0±16.8 |
| Diabetes duration, yr | 10 (5–14) | 7 (4–12) | 10 (5–17) | 10 (6–14) | 10 (6–15) |
| Medication use (%) | |||||
| Aspirin | 54.6 | 54.7 | 53.1 | 55.5 | 55.1 |
| β-Blockers | 27.8 | 24.0 | 22.5 | 30.1 | 34.7 |
| Statins | 63.1 | 55.3 | 68.0 | 64.4 | 64.6 |
| ACEIs | 51.0 | 52.0 | 46.3 | 56.9 | 49.0 |
| Angiotensin receptor blockers | 18.3 | 14.7 | 15.7 | 21.0 | 22.5 |
| Insulin | 34.8 | 28.0 | 35.4 | 38.4 | 37.4 |
| Thiazolidinediones | 19.7 | 18.7 | 15.0 | 22.2 | 23.0 |
| Sulfonylureas | 51.0 | 53.3 | 52.4 | 47.3 | 51.0 |
| Laboratory results | |||||
| Hemoglobin A1C (%) | 8.2±1.0 | 8.3±1.2 | 8.2±0.9 | 8.2±0.9 | 8.1±0.9 |
| Creatinine, mg/dl | 0.86±0.18 | 0.84±0.20 | 0.86±0.18 | 0.87±0.18 | 0.87±0.16 |
| eGFR, ml/min per 1.73 m2 | 90.9±22.7 | 96.4±31.7 | 92.3±19.6 | 89.2±18.9 | 85.5±15.9 |
| UACR, mg/g | 8.2 (5.5–13.6) | 8.8 (6.1–12.8) | 7.9 (5.1–13.2) | 8.3 (5.6–13.7) | 8.2 (5.3–14.0) |
| Phosphate, mg/dl | 3.4±0.5 | 3.3±0.5 | 3.4±0.5 | 3.5±0.5 | 3.6±0.5 |
Values are percentages, means±SDs, or medians (interquartile ranges). Serum creatinine and eGFR values are from the month 4 follow-up visit. ACEIs, angiotensin-converting enzyme inhibitors; UACR, urine albumin-to-creatinine ratio.